Magic Hour
You are here:  Home  >  Biotech  >  Current Article

Europeans nix Amgen’s Evenity over negative trial results

By   /   Friday, June 28th, 2019  /   Comments Off on Europeans nix Amgen’s Evenity over negative trial results

    Print       Email
The European Medicines Agency denied an application by Thousand Oaks biotech giant Amgen and Brussels-based pharmaceutical firm UCB for the drug Evenity to treat patients with severe osteoporosis. The Committee for Medicinal Products for Human Use, or CHMP, said that it was concerned about trial results that showed an increased risk of heart attack or…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Carpinteria-based Procore Technologies moved up from No. 880 last year to No. 697 this year. (Nik Blaskovich)

Procore announces second recent acquisition

Read More →